These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24731567)

  • 1. Efficacy and safety of intensive statin therapy in Chinese patients with atherosclerotic intracranial arterial stenosis: a single-center, randomized, single-blind, parallel-group study with one-year follow-up.
    Zhou P; Lu Z; Gao P; Wang P; Cao Z; Zhang G; Wang S; Feng Y; Wang P
    Clin Neurol Neurosurg; 2014 May; 120():6-13. PubMed ID: 24731567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin treatment and carotid plaque morphology in first-ever atherosclerotic transient ischemic attack/stroke: a case-control study.
    Marchione P; Vento C; Morreale M; Izzo C; Maugeri A; Manuppella F; Romeo T; Giacomini P
    J Stroke Cerebrovasc Dis; 2015 Jan; 24(1):138-43. PubMed ID: 25440329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of lipid-lowering therapy on the progression of intracranial arterial stenosis.
    Tan TY; Kuo YL; Lin WC; Chen TY
    J Neurol; 2009 Feb; 256(2):187-93. PubMed ID: 19271101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes.
    Colivicchi F; Tubaro M; Santini M
    Int J Cardiol; 2011 Oct; 152(1):56-60. PubMed ID: 20674999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
    Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebral blood flow evaluation of intensive rosuvastatin therapy in stroke/transient ischemic attack patients with intracranial arterial atherosclerotic stenosis study: Rationale and design.
    Zhang X; Zhou Y; Zhang S; Ding W; Lou M
    Brain Behav; 2017 Jun; 7(6):e00689. PubMed ID: 28638702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial).
    Pedersen TR; Cater NB; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Lindahl C; Szarek M
    Am J Cardiol; 2010 Aug; 106(3):354-9. PubMed ID: 20643245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy.
    Mega JL; Morrow DA; Cannon CP; Murphy S; Cairns R; Ridker PM; Braunwald E
    J Thromb Thrombolysis; 2006 Aug; 22(1):71-6. PubMed ID: 16786236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
    Ray KK; Cannon CP; McCabe CH; Cairns R; Tonkin AM; Sacks FM; Jackson G; Braunwald E;
    J Am Coll Cardiol; 2005 Oct; 46(8):1405-10. PubMed ID: 16226162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible short-term amelioration of basilar plaque by high-dose atorvastatin: use of reductase inhibitors for intracranial plaque stabilization.
    Callahan AS; Berger BL; Beuter MJ; Devlin TG
    J Neuroimaging; 2001 Apr; 11(2):202-4. PubMed ID: 11296593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin for the treatment of plaque-type psoriasis.
    Faghihi T; Radfar M; Mehrabian Z; Ehsani AH; Rezaei Hemami M
    Pharmacotherapy; 2011 Nov; 31(11):1045-50. PubMed ID: 22026392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised study to compare the efficacy and safety of isapgol plus atorvastatin versus atorvastatin alone in subjects with hypercholesterolaemia.
    Jayaram S; Prasad HB; Sovani VB; Langade DG; Mane PR
    J Indian Med Assoc; 2007 Mar; 105(3):142-5, 150. PubMed ID: 17824470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study.
    Zhao SP; Peng DQ; Yu BL; Huo Y;
    Am Heart J; 2009 Oct; 158(4):509-512.e1. PubMed ID: 19781407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
    Waters DD; Ho JE; Boekholdt SM; DeMicco DA; Kastelein JJ; Messig M; Breazna A; Pedersen TR
    J Am Coll Cardiol; 2013 Jan; 61(2):148-52. PubMed ID: 23219296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose statin therapy for secondary prevention of stroke: stroke prevention by aggressive reduction in cholesterol levels study review.
    Schwertz DW; Badellino KO
    J Cardiovasc Nurs; 2008; 23(1):8-13. PubMed ID: 18158500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease.
    Stoekenbroek RM; Boekholdt SM; Fayyad R; Laskey R; Tikkanen MJ; Pedersen TR; Hovingh GK;
    Heart; 2015 Mar; 101(5):356-62. PubMed ID: 25595417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin decreases computed tomography and S100-assessed brain ischemia after subarachnoid aneurysmal hemorrhage: a comparative study.
    Sanchez-Peña P; Nouet A; Clarençon F; Colonne C; Jean B; Le Jean L; Fonfrede M; Aout M; Vicaut E; Puybasset L
    Crit Care Med; 2012 Feb; 40(2):594-602. PubMed ID: 21926584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.